A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) Meeting Abstract

  

Authors:	Sangro, B.; Harding, J. J.; Johnson, M.; Palmer, D. H.; Edeline, J.; Abou-Alfa, G. K.; Cheng, A. L.; Decaens, T.; El-Khoueiry, A. B.; Finn, R. S.; Galle, P. R.; Park, J. W.; Yau, T.; Begic, D.; Shen, Y.; Neely, J.; Sama, A. R.; Kudo, M.
Abstract Title:	A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC)
Meeting Title:	2021 Gastrointestinal Cancers Symposium (ASCO GI)
Journal Title:	Journal of Clinical Oncology
Volume:	39
Issue:	3 Suppl.
Meeting Dates:	2021 Jan 15-17
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2021-01-20
Language:	English
ACCESSION:	WOS:000636712800034
DOI:	10.1200/JCO.2021.39.3_suppl.TPS349
PROVIDER:	wos
Notes:	Meeting Abstract: TPS349 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/180922